ENDOCRINOLOGICAL DISORDERS AND OBESITY, AND THEIR CONTRIBUTIONS TO DEGENERATIVE JOINT DISEASES

KEBRET T. KEBEDE

MD, FICS, FRSM, Department of Health Sciences, Nevada State University, United States of America
E-mail: kebret.kebede@nevadastate.edu

Abstract - Degenerative joint disease (DJD), commonly referred to as osteoarthritis, is a leading cause of disability worldwide. Increasing evidence highlights the interconnected roles of endocrine disorders and obesity in both the onset and progression of DJD. Endocrine dysfunction, including hypothyroidism, Cushing's syndrome, and polycystic ovary syndrome (PCOS)contributes to metabolic dysregulation and weight gain, which in turn accelerates joint degeneration through mechanical overload, chronic inflammation, and altered adipokine signaling. Nutritional factors further modulate these processes by influencing systemic inflammation, oxidative stress, and cartilage integrity. This review synthesizes current evidence on the pathophysiological links among endocrine disorders, obesity, and DJD, and emphasizes the importance of integrated clinical management strategies targeting hormonal balance, weight reduction, and dietary optimization. A multidisciplinary approach is essential to mitigate disease progression and improve patient outcomes.


Keywords - Osteoarthritis; Degenerative Joint Disease; Obesity; Endocrine Disorders; Inflammation; Metabolism

Degenerative joint disease (DJD), or osteoarthritis, is a progressive musculoskeletal disorder characterized by cartilage degradation, joint pain, and functional impairment. It represents one of the most prevalent causes of disability globally, with significant socioeconomic impact. The pathogenesis of DJD is multifactorial, involving complex interactions among mechanical stress, metabolic dysregulation, and inflammatory pathways. Among the most significant modifiable contributors are obesity and endocrine disorders, both of which have increased markedly in prevalence over recent decades.

Endocrine disorders play a central role in metabolic homeostasis, and their disruption often leads to weight gain and systemic metabolic imbalance. Hypothyroidism, for example, reduces basal metabolic rate and promotes fat accumulation, frequently resulting in persistent weight gain despite lifestyle interventions. Similarly, Cushing's syndrome, characterized by chronic glucocorticoid excess, leads to central adiposity, muscle wasting, and metabolic dysfunction. Polycystic ovary syndrome (PCOS), a common endocrine disorder in women of reproductive age, is strongly associated with insulin resistance, hyperandrogenism, and obesity. These conditions collectively create a metabolic environment that predisposes individuals to chronic inflammation and increased susceptibility to DJD.

Obesity serves as a key intermediary linking endocrine dysfunction to joint degeneration. From a biomechanical perspective, excess body weight imposes increased load on weight-bearing joints such as the knees and hips, accelerating cartilage wear and structural deterioration. Even modest increases in body mass index are associated with significantly elevated risk of osteoarthritis, with evidence suggesting that each additional kilogram of body weight substantially increases joint stress. This mechanical burden alone, however, does not fully explain the relationship between obesity and DJD.

Adipose tissue is now recognized as an active endocrine organ that contributes to systemic inflammation. It secretes a variety of bioactive molecules, including pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha, which promote cartilage degradation and synovial inflammation. In addition, adipokines, including leptin and adiponectin,play critical roles in joint homeostasis. Elevated leptin levels in obese individuals enhance inflammatory signaling and cartilage breakdown, while reduced adiponectin levels diminish protective effects on joint tissues. These biochemical mechanisms significantly amplify the progression of DJD beyond mechanical stress alone.



Psychosocial and behavioral factors further exacerbate disease progression. Chronic joint pain often leads to reduced physical activity, which in turn contributes to further weight gain and metabolic dysfunction. This creates a self-perpetuating cycle in which obesity and joint degeneration reinforce one


another. Additionally, obesity-related stigma and depression may further limit engagement in physical activity and adherence to treatment strategies.

Nutritional factors represent an additional and often underappreciated component in the relationship between endocrine dysfunction, obesity, and DJD. Diets high in refined carbohydrates, saturated fats, and processed foods contribute to systemic inflammation and insulin resistance, thereby accelerating joint degeneration. Conversely, anti-inflammatory dietary patterns rich in fruits, vegetables, whole grains, and omega-3 fatty acids may help mitigate disease progression. Micronutrient deficiencies, particularly in vitamin D, calcium, and magnesium, have been associated with impaired bone and cartilage health and may worsen osteoarthritis outcomes.

Hyperglycemia and insulin resistance, common features of endocrine disorders and obesity, also contribute to cartilage damage through the accumulation of advanced glycation end-products. These compounds alter collagen structure and reduce the mechanical resilience of cartilage, further promoting joint degeneration. The interplay between metabolic and inflammatory pathways underscores the importance of addressing systemic health in the management of DJD.

Given the complex and interconnected nature of these factors, effective management of degenerative joint disease requires a comprehensive and multidisciplinary approach. Early identification and treatment of endocrine disorders are critical to preventing metabolic dysregulation and excessive weight gain. Pharmacologic management of hormonal imbalances, combined with lifestyle interventions, can significantly improve metabolic outcomes.

Weight reduction remains one of the most effective strategies for reducing the burden of DJD. Even modest weight loss has been shown to significantly decrease joint pain and improve function. Physical therapy and low-impact exercise, such as swimming and cycling, play a crucial role in maintaining joint mobility and strengthening periarticular musculature while minimizing mechanical stress.



Nutritional optimization is equally important. Dietary interventions aimed at reducing inflammation and improving metabolic health should be incorporated into treatment plans. Addressing micronutrient deficiencies and promoting balanced macronutrient intake can further support joint health and overall well-being.

Collaboration among healthcare professionals, including endocrinologists, dietitians, physical therapists, and orthopedic specialists—is essential to provide comprehensive care. This multidisciplinary approach allows for individualized treatment strategies that address both systemic and local factors contributing to disease progression.

In conclusion, degenerative joint disease arises from a complex interplay of mechanical, metabolic, endocrine, and nutritional factors. Endocrine disorders contribute to obesity and systemic inflammation, which in turn accelerate joint degeneration through multiple interconnected pathways. Obesity serves as a central mediator in this process, linking hormonal imbalance to biomechanical stress and inflammatory damage. Addressing these factors through integrated clinical strategies is essential for reducing disease burden and improving patient outcomes. Future research should focus on elucidating the molecular mechanisms underlying these relationships and developing targeted interventions that can effectively disrupt this pathogenic continuum.

REFERENCES

[1] Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759.
[2] Wang C, et al. The association of hypothyroidism with obesity. Obes Rev. 2020;21(8):e13014.
[3] Kahaly GJ, et al. Impact of Cushing's syndrome on quality of life. Eur J Endocrinol. 2021;184(2):131–138.
[4] Legro RS, et al. Diagnosis and treatment of PCOS. J Clin Endocrinol Metab. 2020;105(3):1025–1038.
[5] World Health Organization. Obesity and overweight. 2021.
[6] Bannuru RR, et al. OARSI guidelines. Osteoarthritis Cartilage. 2019;27(11):1278–1294.
[7] Duncan R, et al. Weight loss and knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020;28(7):2154–2162.
[8] Guh DP, et al. Obesity-related comorbidities. BMC Public Health. 2009; 9:88.
[9] Kumar A, et al. Obesity and osteoarthritis. Int J Obes. 2020;44(5):1031–1040.
[10] Hernandez CR, et al. Psychological impact of obesity. BMC MusculoskeletDisord. 2020;21(1):1–13.
[11] Cordain L, et al. Dietary inflammation. Am J Clin Nutr. 2005;81(2):341–354.
[12] Veronese N, et al. Diet and osteoarthritis. Clin Nutr. 2019;38(4):1683–1692.
[13] Cao Y, et al. Vitamin D and osteoarthritis. Rheumatology. 2013;52(7):1323–1334.
[14] Heidari B, et al. Micronutrients and joint health. Int Orthop. 2011;35(11):1627–1631.
[15] McAlindon TE, et al. Nutritional factors in OA. Arthritis Rheum. 1996;39(4):648–656.
[16] Calder PC. Omega-3 fatty acids and inflammation. Biochem Soc Trans. 2017;45(5):1105–1115.
[17] Senftleber NK, et al. Fatty acids and arthritis. Arthritis Care Res. 2017;69(5):744–755.

[18] Verzijl N, et al. Advanced glycation end-products. Arthritis Rheum. 2002;46(4):114–123.
[19] Courties A, et al. Metabolic OA mechanisms. Curr OpinRheumatol. 2019;31(2):143–150.
[20] Floyd JA, et al. Endocrine disorders and obesity. J Endocrinol. 2020;245(3):205–217.
[21] Mäkelä M, et al. Obesity and knee osteoarthritis. Clin Rheumatol. 2019;38(3):863–870.

★★★